Page 1

November 26 , 2021 Can - Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update PETACH TIKVA , Israel -- ( BUSINESS WIRE ) -- Can - Fite BioPharma Ltd. ( NYSE American : CANF ) ( TASE : CFBI ) , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory , cancer and liver diseases , today announced financial results for the quarter ended September 30 , 2021 . Corporate and Clinical Development Highlights Include : Completed Patient Enrollment in Phase III Psoriasis Study- The Phase III Comfort ™ study completed patient enrollment . Topline results are expected in Q1 2022. The study is designed to establish Piclidenoson's superiority compared to placebo and non - inferiority compared to Apremilast ( OtezlaⓇ ) in patients with moderate to severe plaque psoriasis . Can - Fite Ends Phase II COVID - 19 Trial to Focus on Core Indications -In 2020 , with the aim of developing a much - needed drug to treat manifestations of COVID - 19 , mainly the Cytokine Release Syndrome , Can - Fite initiated a Phase II COVID - 19 study of its lead drug candidate , Piclidenoson , with patient enrollment in Israel and Europe . With the anticipated launch of Pfizer's oral COVID - 19 antiviral drug candidate , Can - Fite has made a strategic decision to end its COVID - 19 program and to focus its resources on its other clinical programs , all in advanced clinical trials . Patents Granted for NASH in Japan , Hong Kong , and Mexico -Can - Fite continues to build its IP portfolio for NASH which now includes patents granted and allowed in 37 countries . Most recently , patents were issued and allowed in Japan , Hong Kong , and Mexico for the patent titled " An A3 Adenosine Receptor Ligand for Use In Treating Ectopic Fat Accumulation " . This patent addresses the use of the A3 Adenosine Receptor ( A3AR ) ligand , the target receptor for Can - Fite's drug platform technology , in the treatment of NASH . Data on A3AR - based Cannabis Compounds in the Treatment of Liver Diseases Presented at AASLD and Published in HEPATOLOGY - Can - Fite delivered a poster presentation titled “ Growth Inhibition of Hepatocellular Carcinoma ( HCC ) by CBD Rich T3 / C15 Cannabis Fraction is Mediated via the A3 Adenosine Receptor ” at the American Association for the Study of Liver Diseases ( AASLD ) The Liver MeetingⓇ during the Hepatobiliary Neoplasia : Experimental Hepatocarcinogenesis ; Diagnostics and Liver Imaging session . The findings were also published in an abstract in the October 2021 supplement of HEPATOLOGY , a premier peer - reviewed publication in the field of liver disease published on behalf of the AASLD . Positive Phase lla NASH Data Published in Alimentary Pharmacology & Therapeutics - The peer - reviewed scientific journal focused on gastroenterology and hepatology published an article titled " Randomised clinical trial : A phase 2 double - blind study of namodenoson in non - alcoholic fatty liver disease and steatohepatitis " . The article includes